Literature DB >> 21600380

Other options in the treatment of advanced breast cancer.

Melody A Cobleigh1.   

Abstract

Many cytotoxic therapies are available for patients with metastatic breast cancer, but response rates are low and acquired or de novo resistance is virtually universal. Among the agents that are used in the treatment of pretreated metastatic breast cancer are vinorelbine, gemcitabine, nab-paclitaxel, pemetrexed, platinum salts (eg, cisplatin, carboplatin), pegylated liposomal doxorubicin, etoposide, and irinotecan. Therapies that improve overall survival in patients with anthracycline- and taxane-resistant metastatic breast cancer are needed.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21600380     DOI： 10.1053/j.seminoncol.2011.04.005

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


  21 in total

1.  BRCA1 functions independently of homologous recombination in DNA interstrand crosslink repair.

Authors:  Samuel F Bunting; Elsa Callén; Marina L Kozak; Jung Min Kim; Nancy Wong; Andrés J López-Contreras; Thomas Ludwig; Richard Baer; Robert B Faryabi; Amy Malhowski; Hua-Tang Chen; Oscar Fernandez-Capetillo; Alan D'Andrea; André Nussenzweig
Journal:  Mol Cell       Date:  2012-03-22       Impact factor: 17.970

2.  A comparative analysis on the efficacy and safety of intaxel® and taxol® in advanced metastatic breast cancer.

Authors:  Istvan Lang; Gabor Rubovszky; Zsolt Horvath; Erna Ganofszky; Eszter Szabo; Magdolna Dank; Katalin Boer; Erika Hitre
Journal:  J Clin Diagn Res       Date:  2013-06-01

3.  MiR-363 sensitizes cisplatin-induced apoptosis targeting in Mcl-1 in breast cancer.

Authors:  Ruiguang Zhang; Yan Li; Xiaochuan Dong; Li Peng; Xiu Nie
Journal:  Med Oncol       Date:  2014-11-22       Impact factor: 3.064

4.  Stearoyl gemcitabine nanoparticles overcome obesity-induced cancer cell resistance to gemcitabine in a mouse postmenopausal breast cancer model.

Authors:  Rebecca E De Angel; Jorge M Blando; Matthew G Hogan; Michael A Sandoval; Dharmika S P Lansakara-P; Sarah M Dunlap; Stephen D Hursting; Zhengrong Cui
Journal:  Cancer Biol Ther       Date:  2013-01-28       Impact factor: 4.742

5.  Knockdown of miR-221 promotes the cisplatin-inducing apoptosis by targeting the BIM-Bax/Bak axis in breast cancer.

Authors:  Zhiqiang Ye; Rutian Hao; Yefeng Cai; Xiaobo Wang; Guanli Huang
Journal:  Tumour Biol       Date:  2015-10-26

Review 6.  Immunotherapy of cancer: reprogramming tumor-immune crosstalk.

Authors:  Kyle K Payne; Amir A Toor; Xiang-Yang Wang; Masoud H Manjili
Journal:  Clin Dev Immunol       Date:  2012-10-11

7.  Rhodacyanine derivative selectively targets cancer cells and overcomes tamoxifen resistance.

Authors:  John Koren; Yoshinari Miyata; Janine Kiray; John C O'Leary; Lana Nguyen; Jianping Guo; Laura J Blair; Xiaokai Li; Xiokai Li; Umesh K Jinwal; Jin Q Cheng; Jason E Gestwicki; Chad A Dickey
Journal:  PLoS One       Date:  2012-04-26       Impact factor: 3.240

8.  Targeted drug delivery systems mediated by a novel Peptide in breast cancer therapy and imaging.

Authors:  Ruei-Min Lu; Min-Shan Chen; De-Kuan Chang; Chien-Yu Chiu; Wei-Chuan Lin; Shin-Long Yan; Yi-Ping Wang; Yuan-Sung Kuo; Chen-Yun Yeh; Albert Lo; Han-Chung Wu
Journal:  PLoS One       Date:  2013-06-11       Impact factor: 3.240

9.  Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-κB and HSP27/p38/AKT pathways and by inhibiting ABCB1.

Authors:  Jonathan T Sims; Sourik S Ganguly; Holly Bennett; J Woodrow Friend; Jessica Tepe; Rina Plattner
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

10.  Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer.

Authors:  Ibrahim Tekedereli; S Neslihan Alpay; Clint D J Tavares; Zehra E Cobanoglu; Tamer S Kaoud; Ibrahim Sahin; Anil K Sood; Gabriel Lopez-Berestein; Kevin N Dalby; Bulent Ozpolat
Journal:  PLoS One       Date:  2012-07-20       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.